(2S)-4-[(2-aminoacetyl)amino]-N-(4-tert-butylphenyl)pyrrolidine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-4-[(2-aminoacetyl)amino]-N-(4-tert-butylphenyl)pyrrolidine-2-carboxamide
• 化学式: C₁₇H₂₆N₄O₂
• 分子量: 318.4
• InChiKey: ABDGMDJFZLBZJS-KZUDCZAMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  96.2
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
  申请人：Rhode Island Hospital

  公开号：US11419834B2

  公开（公告）日：2022-08-23

  Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. pylori in a subject infected by H. pylori, the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.

  本发明公开了用于预防或治疗被幽门螺杆菌感染的受试者中由幽门螺杆菌引起或与之相关的疾病或感染的方法，该方法包括向受试者口服卤代水杨酰苯胺，例如尼可刹米。该方法可用于预防或治疗例如消化不良、胃炎、消化性溃疡病、胃癌前病变、胃癌和胃黏膜相关淋巴组织（MALT）淋巴瘤。
• ANTIBACTERIAL COMPOUNDS
  申请人：Victoria Link Limited

  公开号：EP3220919A1

  公开（公告）日：2017-09-27
• Antibacterial Compounds
  申请人：VICTORIA LINK LIMITED

  公开号：US20190328687A1

  公开（公告）日：2019-10-31

  The present invention relates to salicylamide compounds and compositions thereof effective in targeting growth of bacteria. The compounds and compositions of the present invention are particularly useful in, for example, the prevention or treatment of bacterial infection and the prevention, reduction or elimination of biofilm formation.
• METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE
  申请人：Rhode Island Hospital

  公开号：US20200268693A1

  公开（公告）日：2020-08-27

  Disclosed are methods for the prevention or treatment of a disease or infection caused by or associated with H. Pylori in a subject infected by H. Pylori , the method comprising orally administering a halogenated salicylanilide such as niclosamide to the subject. The method may be used for the prevention or treatment of, for example dyspepsia, gastritis, peptic ulcer disease, premalignant gastric lesions, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
• TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE
  申请人：UNION therapeutics A/S

  公开号：US20210137948A1

  公开（公告）日：2021-05-13

  The present invention relates to halogenated salicylanilides, such as closantel, rafoxanide, oxyclozanide, niclosamide, or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of an infection caused by N. gonococcus bacteria in a subject, such as treatment of gonococcal conjunctivitis or anorectal gonorrhoea.